Company / Free Cash Flow
NeoGenomics Laboratories, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$21.8M
FY2025
5-year range
-$96.9M / -$21.8M
FY2021-FY2025
Trend
+36.0%
vs FY2024
Sector context
#124 of 151
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s free cash flow of -$22M is lower than 82% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 10 years, ranging from -$97M in FY2022 to $30M in FY2018.
Based on SEC 10-K filings.
-$22M in FY2025.
Improved from -$31M to -$22M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 151This company -$21.8M Sector average $779.8M
▼
-102.8% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 36.0% year-over-year.
- Ranks #124 out of 151 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2018.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$21.8M | +36.0% |
| FY2024 | -$34.0M | -10.9% |
| FY2023 | -$30.7M | +68.3% |
| FY2022 | -$96.9M | -6.6% |
| FY2021 | -$90.9M | -228.8% |
| FY2020 | -$27.6M | -927.4% |
| FY2019 | $3.3M | -89.0% |
| FY2018 | $30.5M | +601.1% |
| FY2017 | $4.3M | -68.8% |
| FY2016 | $13.9M | +233.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026